Biomarker association with disease progression places tau accumulation at the earliest stages of dementia, while the density and spatial distribution of hyperphosphorylated tau have been linked to cognitive decline 4-6,8, thus making tau an attractive therapeutic target 9. The gene discussed is MAPT; the disease is Mental deterioration.